| Secondary |
| Epilepsy |
33.9% |
| Convulsion |
12.0% |
| Prophylaxis |
9.3% |
| Hypertension |
6.1% |
| Product Used For Unknown Indication |
5.9% |
| Pneumonia |
4.6% |
| Cerebral Infarction |
3.2% |
| Constipation |
2.7% |
| Depression |
2.4% |
| Drug Use For Unknown Indication |
2.2% |
| Gastric Ulcer |
2.0% |
| Glioblastoma Multiforme |
2.0% |
| Status Epilepticus |
2.0% |
| Brain Neoplasm |
1.9% |
| Cardiac Failure |
1.9% |
| Encephalitis Herpes |
1.9% |
| Hyperlipidaemia |
1.9% |
| Altered State Of Consciousness |
1.5% |
| Stem Cell Transplant |
1.5% |
| Acute Respiratory Distress Syndrome |
1.3% |
|
| Stevens-johnson Syndrome |
9.3% |
| White Blood Cell Count Increased |
9.3% |
| Drug Eruption |
8.3% |
| Toxic Epidermal Necrolysis |
7.4% |
| White Blood Cell Count Decreased |
6.5% |
| Epilepsy |
5.6% |
| Rash |
5.6% |
| Therapeutic Agent Toxicity |
5.6% |
| Agranulocytosis |
4.6% |
| Interstitial Lung Disease |
4.6% |
| Pyrexia |
4.6% |
| Renal Impairment |
4.6% |
| Multi-organ Failure |
3.7% |
| Somnolence |
3.7% |
| Bicytopenia |
2.8% |
| Drug Interaction |
2.8% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.8% |
| Encephalopathy |
2.8% |
| Gait Disturbance |
2.8% |
| Liver Disorder |
2.8% |
|
| Concomitant |
| Epilepsy |
34.1% |
| Drug Use For Unknown Indication |
13.0% |
| Complex Partial Seizures |
5.4% |
| Prophylaxis |
5.1% |
| Product Used For Unknown Indication |
4.6% |
| Hypertension |
4.5% |
| Simple Partial Seizures |
4.5% |
| Partial Seizures With Secondary Generalisation |
4.0% |
| Convulsion |
3.3% |
| Pneumonia |
2.8% |
| Glioblastoma Multiforme |
2.7% |
| Constipation |
2.5% |
| Grand Mal Convulsion |
2.4% |
| Gastric Ulcer |
2.0% |
| Partial Seizures |
1.8% |
| Central Nervous System Lymphoma |
1.5% |
| Cerebral Palsy |
1.5% |
| Mental Retardation Severity Unspecified |
1.5% |
| Encephalitis Herpes |
1.4% |
| Insomnia |
1.4% |
|
| Status Epilepticus |
13.8% |
| White Blood Cell Count Decreased |
10.5% |
| White Blood Cell Count Increased |
7.1% |
| Pneumonia |
6.3% |
| Hepatic Function Abnormal |
5.9% |
| Convulsion |
5.4% |
| Epilepsy |
5.4% |
| Renal Impairment |
4.2% |
| Somnolence |
4.2% |
| Interstitial Lung Disease |
3.8% |
| Loss Of Consciousness |
3.8% |
| Pancytopenia |
3.8% |
| Platelet Count Decreased |
3.8% |
| Pneumonia Aspiration |
3.8% |
| Pyrexia |
3.8% |
| Rhabdomyolysis |
3.3% |
| Depressed Level Of Consciousness |
2.9% |
| Sepsis |
2.9% |
| Staphylococcal Infection |
2.9% |
| Rash |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
40.8% |
| Pseudomonas Infection |
15.8% |
| Colon Cancer |
9.2% |
| Injury |
7.9% |
| Fungal Infection |
6.6% |
| Drug Use For Unknown Indication |
5.3% |
| Abscess |
3.9% |
| Convulsion |
3.9% |
| Staphylococcal Infection |
3.9% |
| Large Intestine Carcinoma |
2.6% |
|
| Status Epilepticus |
35.3% |
| Convulsion |
17.6% |
| Vomiting |
17.6% |
| Drug Toxicity |
11.8% |
| Somnolence |
5.9% |
| Vertigo |
5.9% |
| Visual Impairment |
5.9% |
|
